These results indicate that the effect of PAC treatment on prostate cancer is mainly achieved by adjusting the expression of PSA, AR, COX-2, Bcl-2, and caspase3, and by further inhibiting the inflammatory microenvironment in vivo, finally inhibiting prostate cancer cell proliferation and inducing prostate cancer cell apoptosis, offering further effective intervention in the growth of prostate cancer xenograft tumours. The gene discussed is BCL2; the disease is Familial prostate cancer.